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Abstract Cleavage of the envelope glycoprotein precursor
gp160 of HIV-1 is a prerequisite for the infectivity of HIV-1,
and occurs at least in part before gp160 reaches the cell surface.
Kexin/subtilisin-related endopeptidases are proposed enzyme
candidates for this intracellular processing. In this study, we
reveal the possibility that plasminogen binds to the cell surface
and part of gp160 escaping intracellular processing is cleaved by
plasmin extracellularly. Plasmin cleaves gp160 precisely at the
C-terminal arginine residue of gp120, and the processing is
effectively inhibited by an analogue peptide of the cleavage motif
(RXK/RR) and by plasmin inhibitors.
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1. Introduction
The processing of the HIV-1 envelope glycoprotein gp160
has been proposed to be an essential step in the production of
infectious viral particles [1,2]. As in the case of other retro-
viruses, the envelope glycoprotein of HIV-1 is synthesized as a
precursor polypeptide (gp160) that is cleaved by a protease at
a site in the multi-basic motif (RXK/RR) between gp120 and
gp41. To date, kexin/subtilisin-related endopeptidases and vi-
ral envelope glycoprotein maturase (VEM), which are propro-
tein convertases in the Golgi apparatus, have been shown to
be processing proteases for HIV-1 gp160 [3^10], and inhibi-
tors of these enzymes, candidates for the treatment of AIDS,
suppress multiple cycles of HIV-1 replication, thus inhibiting
the spread of HIV. However, part of gp160 escapes intracel-
lular processing and is transported to the cell surface and/or
secreted into the extracellular milieu [11]. In this regard, we
hypothesized a cell-surface proteolytic activation mechanism
for gp160, and searched for an extracellular processing pro-
tease that converts gp160 to gp120 and gp41. The results show
that only plasmin among the extracellular trypsin-like pro-
teases tested is a processing enzyme for gp160. Plasminogen
in serum binds to the surface of human T cells and is con-
verted to plasmin. This processing of gp160 is inhibited by the
plasmin inhibitors aprotinin and HI-30, and by a substrate
analogue, decanoyl (dec)-RVKR-chloromethyl ketone (cmk).
Judging from these results, unprocessed gp160 on the cell sur-
face, which has escaped intracellular processing and/or has
resulted from the inhibition of intracellular processing by in-
hibitors of kexin/subtilisin-related endopeptidases and VEM,
is converted to gp120 and gp41 on the cell surface by human
plasmin.
2. Materials and methods
2.1. Materials
Glycosylated recombinant HIV-1(IIIB) gp160, which is produced in
insect cells using the baculovirus expression system, was purchased
from MicroGeneSys, Inc. (West Haven, CT, USA). Anti-gp41 mono-
clonal antibody (mAb) was from Daiichi Pure Chemicals (Tokyo,
Japan). Anti-bovine plasminogen antibody, which reacts with both
plasminogen and plasmin, was from American Diagnostica (Green-
wich, CT, USA). Human plasmin was purchased from Boehringer
Mannheim Biochemicals (Mannheim, Germany). Urokinase and pro-
tease inhibitors, aprotinin, K1-antitrypsin, and chymostatin were from
Sigma Chemical Co. (St. Louis, MO, USA). Leupeptin, N-tert-butyl-
oxycarbonyl (Boc)-LKR-4-methylcoumaryl-7-amide (MCA), and
Boc-RVRR-MCA were from the Peptide Institute (Osaka, Japan).
Inhibitors of furin, dec-RVKR-cmk and dec-FAKR-cmk, which are
analogue peptides of the multi-basic cleavage motif RXK/RR found
in various prohormones and retrovirus envelope glycoprotein precur-
sors, were a gift from Dr. H.D. Klenk, University of Marburg (Ger-
many). HI-30 was a gift from Prof. H. Fritz, University of Munich
(Germany). Tryptase from human lung was puri¢ed to homogeneity
by the method of Smith et al. [12]. Thrombin and factor Xa from
bovine plasma were puri¢ed by the method of Hashimoto et al. [13].
2.2. Cell culture
Molt-4, clone 8 cells were cultured in RPMI 1640 medium (Nissui
Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% fetal
calf serum (FCS) or in serum-free GIT medium (Wako, Osaka, Japan)
at 37‡C with 5% CO2. The cells in the early stationary phase after ¢ve
passages were collected by centrifugation, washed twice with saline
and used for subcellular fractionation.
2.3. Preparation of membrane fraction of human T cells
Molt-4, clone 8 cells (1U108) cultured in RPMI 1640 medium sup-
plemented with 10% FCS or in serum-free medium were homogenized
with 10 volumes of 10 mM Tris-HCl bu¡er, pH 7, containing 135 mM
NaCl without MgCl2 in a Potter-Elvehjem homogenizer at 0‡C. The
homogenate was centrifuged at 12 000Ug for 60 min to remove nu-
cleus, mitochondria, lysosomes and a large portion of microsomes,
and the supernatant was further centrifuged at 105 000Ug for 1 h.
Under the conditions used, the precipitate is mainly composed of
plasma membrane. The precipitate was then suspended in 2 ml of
0.1 M Tris-HCl bu¡er, pH 8.5, homogenized and centrifuged at
105 000Ug for 30 min. The resulting supernatant was used for the
analysis of gp160 processing.
2.4. Conversion of gp160 to gp120 and gp41
The gp160 (1.0 Wg) was incubated with various proteases (1.35pmol)
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for 7.5^30 min at 37‡C under optimal reaction conditions for each
enzyme in 20 Wl of bu¡er (plasmin and urokinase, 0.1 M Tris-HCl
bu¡er, pH 7.0; human lung tryptase, 0.1 M Tris-HCl bu¡er, pH 7.5,
containing 0.15 M NaCl and 2.5 Wg/ml heparin; thrombin, 50 mM
Tris-HCl bu¡er, pH 7.8, containing 0.1 M NaCl and 20 mM EDTA;
and factor Xa, 50 mM Tris-HCl bu¡er, pH 7.5, containing 0.15 M
NaCl and 10 mM CaCl2). The enzyme/substrate ratios were 1:10. For
assays of gp160 processing by membrane fraction, aliquots of the
membrane fraction of human T cells (80 Wg) were incubated with
0.1 Wg of 125I-labeled gp160 prepared with Iodo-Beads [10] in 20 Wl
of 100 mM Tris-HCl, pH 7, and then incubated at 37‡C for 5^10 h.
The reactions were terminated by cooling on ice and adding 6USDS-
PAGE sample loading bu¡er [14]. The reaction mixtures were then
subjected to SDS-PAGE under reducing conditions and analyzed by
Western immunoblotting.
2.5. Electrophoresis and Western immunoblotting
SDS-PAGE (4^20% gradient gel; Daiichi Pure Chemicals) was per-
formed at room temperature by the method of Laemmli [14]. The
SDS-PAGE high range standards (Bio-Rad) used as molecular weight
markers were myosin (213 kDa), L-galactosidase (119 kDa), bovine
serum albumin (BSA) (83 kDa), and ovalbumin (47 kDa). For West-
ern blot analysis, the reaction samples were subjected to SDS-PAGE,
and then transferred electrophoretically to an Immobilon transfer
membrane (Millipore); excess sites were blocked with 3.5% skim
milk in PBS. The membrane was then probed with a mAb against
gp41, 1:200, in 1% BSA in Tris-bu¡ered saline (TBS: 20 mM Tris-
HCl bu¡er, pH 7.5/0.5 M NaCl) overnight at 4‡C. After extensive
washing with TBS, the membrane was reproved with anti-mouse
IgG conjugated with horseradish peroxidase (Amersham, Amersham,
UK), 1:1000, in 3.5% skim milk in PBS for 1 h at room temperature.
The bound antibodies were detected with ECL Western blotting de-
tection reagents (Amersham, Amersham, UK) according to the manu-
facturer’s instructions.
2.6. Amino acid sequences
The N-terminal amino acid sequences of the proteolytic products
were determined by the microsequencing method with an Applied
Biosystems 492 model gas-phase sequencer/140C high performance
liquid chromatography system after the reaction samples had been
electrophoretically transferred to a ProBlot membrane (Applied Bio-
systems, Foster City, CA) according to the manufacturer’s instruc-
tions.
2.7. Inhibition of gp160 processing
The gp160 (1.0 Wg) was incubated with plasmin (1.35 pmol) in
reaction bu¡er in the presence or absence of protease inhibitors (10
WM) for 30 min at 37‡C, and the reaction was terminated by cooling
on ice and adding 6USDS-PAGE sample loading bu¡er [14]. The
samples were then subjected to SDS-PAGE under reducing conditions
and analyzed by Western immunoblotting.
2.8. Flow cytometry
Molt-4, clone 8 cells (1U106) cultured in RPMI 1640 medium sup-
plemented with 10% FCS or in serum-free GIT medium were incu-
bated with or without anti-bovine plasminogen antibody, 1:10, in
3.5% skim milk in PBS for 1 h at 4‡C followed by anti-goat IgG
conjugated with FITC, for 30 min as described [15]. They were then
washed three times with PBS by centrifugation (300Ug for 1 min),
resuspended in 0.6 ml of 1% paraformaldehyde in saline, and analyzed
with a EPICS Elite ESP model cell sorter (Coulter).
3. Results and discussion
3.1. Selective conversion of gp160 to gp120 and gp41 by human
plasmin
We examined the e¡ects of various extracellular trypsin-
type proteases on the processing of gp160 (Fig. 1A). Among
the extracellular processing proteases tested, human plasmin
(lane 2) speci¢cally converted gp160 to gp120 and gp41. The
other extracellular proteases and secretory proteases tested,
including human lung tryptase, thrombin, factor Xa, and uro-
kinase, did not give gp41. We then examined the time course
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Fig. 1. Processing of gp160 by extracellular trypsin-type proteases.
A: E¡ect of various extracellular proteases on gp160. gp160 (1.0
Wg) (lane 1) was incubated for 30 min with various extracellular
and/or secretory proteases (1.35 pmol) including plasmin (lane 2),
human lung tryptase (lane 3), thrombin (lane 4), factor Xa (lane 5),
and urokinase (lane 6). The reaction products were separated by
SDS-PAGE followed by detection by Western immunoblotting. B:
Time course of gp160 processing by human plasmin. gp160 (1.0 Wg)
(lane 1) was incubated with plasmin (1.35 pmol) for 0 (lane 2), 7.5
(lane 3), 15 (lane 4), or 30 min (lane 5), and then subjected to SDS-
PAGE and Western immunoblotting. C: The N-terminal sequence
of the gp41 generated by plasmin was analyzed as described in Sec-
tion 2, and is indicated in bold letters. The aligned amino acid se-
quence is the sequence of HIV-1(IIIB) gp160 [22]. The multi-basic
cleavage motif of gp160 is underlined.
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of gp160 processing by plasmin, and the products were ana-
lyzed by Western immunoblotting with a mAb against gp41
(Fig. 1B). As expected, the amount of gp160 decreased in a
time-dependent manner along with an increase in gp41.
To determine the cleavage site of gp160 by human plasmin,
the N-terminal amino acid sequence of the protein with a
molecular mass of 41 kDa, which corresponds to gp41, was
analyzed (Fig. 1C). Although the protein band was di¡use
because it is a glycoprotein, a single amino acid sequence
was detected without contamination. The sequence of the 41
kDa fragment revealed A(4.6)-V(4.5)-G(4.2)-I(3.8)-G(4.1)-
A(3.9)-L(3.6)-F(3.2)-L(3.5)-G(3.3)-F(3.1) (the values in paren-
theses are the yields in pmol). This indicates that the R511^
A512 bond on the C-terminal side of the multi-basic cleavage
motif R508EKR511 between gp120 and gp41 is selectively
cleaved by human plasmin. Another sequence of clustered
basic amino acids, K502RRVV506, was found not to be suscep-
tible to this enzyme. This site cleaved by human plasmin is the
same site as that cleaved by kexin/subtilisin-related endopep-
tidases and VEM [4^6,10]. This ¢nding is supported by our
previous data that plasmin exhibits similar Km values for a
synthetic plasmin substrate (Boc-LKR-MCA) (Km = 4.2U
1034 M) and a synthetic kexin/furin substrate (Boc-RVRR-
MCA) (Km = 4.8U1034 M) [16]. Taken together, the results
indicate that the consensus cleavage motif of gp160,
R508EKR511, is recognized by human plasmin, and that the
R511^A512 bond is cleaved by the enzyme.
To determine the biological activity of gp120 produced
after the processing, we analyzed the a⁄nity constant for
the interaction between gp120 and soluble CD4 as described
[17]. Scatchard analyses revealed a single class of binding with
an apparent dissociation constant (Kd) of 8.3 nM for soluble
CD4 and this value was comparable to that reported [18].
3.2. Binding of plasminogen to the cell surface and conversion
of gp160 to gp120 and gp41 by the membrane fraction
We next attempted to directly detect binding of plasmino-
gen to the membrane of Molt-4, clone 8 cells cultured in
RPMI 1640 medium supplemented with 10% FCS. By £uo-
rescence-activated cell-sorting analyses, plasminogen and/or
plasmin was detected on the membrane but not on that of
the cells cultured in serum-free GIT medium (Fig. 2A,B, re-
spectively). So far there was no antibody that can distinguish
between plasminogen and plasmin, these immunoreactive pro-
teins in the membrane fraction were subjected to SDS-PAGE
followed by detection by Western immunoblotting. The mem-
brane fractions of Molt-4, clone 8 cells cultured in RPMI 1640
medium supplemented with 10% FCS revealed a main immu-
noreactive protein band with a molecular mass of plasmino-
gen and minor immunoreactive protein bands with molecular
masses of two subunits of plasmin (data not shown). How-
ever, plasminogen and plasmin in the membrane fractions of
the cells cultured in serum-free medium were not detected at
all.
The membrane fractions of the cells cultured in the medium
supplemented with 10% FCS but not those of the cells cul-
tured in serum-free medium converted gp160 to gp120 and
gp41 (Fig. 2C) and this conversion was completely inhibited
by plasmin inhibitors aprotinin and HI-30, an active fragment
FEBS 21357 4-1-99
Fig. 2. Binding of plasminogen to the cell surface (A and B) and processing of gp160 by the membrane fraction (C). A and B: Molt-4, clone
8 cells were cultured in RPMI 1640 medium supplemented with 10% FCS (A) or in serum-free GIT medium (B) and bound plasminogen
and/or plasmin on these cells after ¢ve passages was detected by anti-bovine plasminogen antibody and FITC-labeled anti-goat antibody under
the conditions given in Section 2. Cells were then analyzed by £ow cytometry. The thin line indicates control cells treated with bu¡er alone,
while the thick line refers to cells treated with anti-plasminogen antibody and FITC-labeled second antibody. The dotted line indicates cells
treated with FITC-labeled second antibody alone. C: Membrane fraction (80 Wg) of cells cultured in RPMI 1640 medium supplemented with
10% FCS (lane 2) and that of the cells in serum-free GIT medium (lane 3) were incubated with 0.1 Wg of 125I-labeled gp160 (lane 1) at 37‡C
for 10 h under the conditions given in Section 2. The reactions were then subjected to SDS-PAGE (4^20% gradient gel).
Fig. 3. Inhibition of gp160 processing by various protease inhibitors
and substrate analogues. gp160 (1.0 Wg) (lane 1) was incubated for
30 min with plasmin (1.35 pmol) in the absence (lane 2) or presence
of various inhibitors and substrate analogues (10 WM) including
dec-RVKR-cmk (lane 3), dec-FAKR-cmk (lane 4), aprotinin (lane
5), leupeptin (lane 6), HI-30 (lane 7), K1-antitrypsin (lane 8), and
chymostatin (lane 9). The reactions were then subjected to SDS-
PAGE and Western immunoblotting.
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of human inter-K-trypsin inhibitor (data not shown). The re-
sults were consistent with those in Fig. 3.
3.3. Inhibition of gp160 processing by natural inhibitors and
synthetic peptides
We further analyzed the e¡ect of various natural and fungal
serine protease inhibitors and substrate analogue peptides on
gp160 processing by human plasmin. As shown in Fig. 3, this
processing is markedly inhibited by the natural plasmin inhib-
itors aprotinin and HI-30, as well as by a substrate analogue,
dec-RVKR-cmk, having basic amino acids at the P1, P2, and
P4 positions. However, another substrate analogue tested,
dec-FAKR-cmk, which has phenylalanine at the P4 position
instead of a basic amino acid, and the other serine protease
inhibitors tested, leupeptin, chymostatin, and K1-antitrypsin,
caused little inhibition of the processing. In addition to the
importance of a basic amino acid at the P1 position of the
cleavage site [1,2], the data imply that a basic amino acid at
the P4 position of the motif may also be important for proc-
essing by plasmin. The Ki values of aprotinin and dec-RVKR-
cmk against plasmin are 5.3U1039 M and 1.3U1036 M, re-
spectively [16].
These data suggest that plasmin plays a role in the process-
ing of gp160 on the cell surface, in addition to kexin/subtilisin-
related endopeptidases and VEM, which convert gp160 to
gp120 and gp41 intracellularly. The cell surface plasmin for-
mation is controlled by urokinase-type plasminogen activator
(uPA) [19]. Indeed, it has recently been reported that freshly
isolated T lymphocytes and monocytic cells from HIV-posi-
tive donors show an increase in the expression of uPA recep-
tor [20,21], and, hence, this may increase in the expression of
cell surface-bound uPA and thus plasmin formation, which in
turn facilitates conversion of gp160 to the mature forms on
the plasma membrane. To evaluate the role of the extracellu-
lar gp160 processing by human plasmin in production of in-
fectious viral particles, further studies on determination of the
amount of gp160 on the cell surface, that has escaped from
intracellular processing in HIV-1-infected cells and those cells
treated with inhibitors of kexin/subtilisin-related endopepti-
dase and VEM, are now in progress. Besides proteolysis on
the cell surface being involved in processes like adhesion, che-
motaxis and migration that are important for viral spreading,
cell surface processing of gp160 by plasmin may also provide
a speci¢c advantage to HIV.
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